Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board expanded from seven to eight directors with Timothy Coughlin appointed as Class III director through the 2028 annual meeting.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from seven to eight directors with Timothy Coughlin appointed as Class III director through the 2028 annual meeting
- Coughlin named Audit Committee Chair, strengthening financial oversight and governance leadership
- New director receives standard cash compensation plus stock options and restricted stock units under the 2019 Equity Incentive Plan
- Appointment not tied to undisclosed arrangements; no reportable related-party transactions identified
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.